1. Aurora-A amplification associated with BRCA2 mutation in breast tumours
- Author
-
Sigridur K. Bodvarsdottir, Jon G. Jonasson, Valgerdur Birgisdottir, Holmfridur Hilmarsdottir, Margret Steinarsdottir, and Jorunn E. Eyfjord
- Subjects
Heterozygote ,Cancer Research ,endocrine system diseases ,DNA Mutational Analysis ,Breast Neoplasms ,Protein Serine-Threonine Kinases ,Biology ,Tp53 mutation ,Cell Line ,BRCA2 Mutation ,Breast cancer ,Mutation Carrier ,Aurora Kinases ,Odds Ratio ,medicine ,Humans ,skin and connective tissue diseases ,neoplasms ,Metaphase ,In Situ Hybridization, Fluorescence ,BRCA2 Protein ,Gene Amplification ,Breast tumours ,medicine.disease ,female genital diseases and pregnancy complications ,Oncology ,Mutation ,Mutation (genetic algorithm) ,Cancer research ,%22">Fish ,Female ,Tumor Suppressor Protein p53 ,biological phenomena, cell phenomena, and immunity - Abstract
Potential interaction of Aurora-A amplification and BRCA2 mutation was examined in breast tumours from BRCA2 999del5 mutation carriers (n = 20) and non-carriers (n = 41). Aurora-A amplification studied by FISH was significantly more common in breast tumours from BRCA2 mutation carriers (p = 0.0005). Extensive Aurora-A amplification was also detected on metaphase chromosomes in three breast epithelial cell lines with the same BRCA2 mutation. In addition, significant association was found between Aurora-A amplification and TP53 mutations in non-BRCA2 mutation carrier tumours (p = 0.007). These results suggest that breast tumours with mutations in BRCA2 or TP53 could be promising candidates for Aurora-A targeted treatment.
- Published
- 2007